期刊
JOURNAL OF INFECTIOUS DISEASES
卷 217, 期 3, 页码 451-455出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jix592
关键词
Ebola virus; vaccine; immunization; RNA; antibody response
资金
- Moderna Therapeutics
- National Institutes of Health [1R01AI102887-01A1]
Most current Ebola virus (EBOV) vaccine candidates are based on viral vectors, some of which cause side effects or require complex manufacturing. Modified mRNA vaccines are easily produced, safe, and are highly immunogenic. We developed 2 mRNA vaccines based on the EBOV envelope glycoprotein, which differed by the nature of signal peptide for improved glycoprotein post-translational translocation. The mRNAs were formulated with lipid nanoparticles to facilitate delivery. Vaccination of guinea pigs induced EBOV-specific IgG and neutralizing antibody responses and 100% survival after EBOV infection. The efficacy of our mRNA vaccine combined with preclinical safety data supports testing in clinical studies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据